Galmed Pharma (GLMD) Misses Q4 EPS by 5c

Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• JPMorgan Downgrades Rockwool (ROCKB:DC) (RKWBF) to Neutral
• Jefferies Downgrades Pop Mart International Group Ltd (9992:HK) to Hold